Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Other Non-Current Liabilities (2022 - 2025)

Historic Other Non-Current Liabilities for Serina Therapeutics (SER) over the last 4 years, with Q2 2025 value amounting to $3.5 million.

  • Serina Therapeutics' Other Non-Current Liabilities fell 7354.06% to $3.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $3.5 million, marking a year-over-year decrease of 7354.06%. This contributed to the annual value of $3.6 million for FY2024, which is N/A changed from last year.
  • Per Serina Therapeutics' latest filing, its Other Non-Current Liabilities stood at $3.5 million for Q2 2025, which was down 7354.06% from $2.6 million recorded in Q1 2025.
  • Serina Therapeutics' Other Non-Current Liabilities' 5-year high stood at $13.4 million during Q2 2024, with a 5-year trough of $180000.0 in Q4 2022.
  • For the 4-year period, Serina Therapeutics' Other Non-Current Liabilities averaged around $3.4 million, with its median value being $2.1 million (2022).
  • Per our database at Business Quant, Serina Therapeutics' Other Non-Current Liabilities tumbled by 7851.39% in 2023 and then tumbled by 7354.06% in 2025.
  • Serina Therapeutics' Other Non-Current Liabilities (Quarter) stood at $180000.0 in 2022, then skyrocketed by 92.78% to $347000.0 in 2023, then skyrocketed by 932.28% to $3.6 million in 2024, then decreased by 0.92% to $3.5 million in 2025.
  • Its last three reported values are $3.5 million in Q2 2025, $2.6 million for Q1 2025, and $3.6 million during Q4 2024.